POZEN, Inc., a development stage company, focuses on the development of products for the treatment of acute and chronic pain, and other pain-related conditions. The company is also exploring the development of product candidates in other pain-related therapeutic areas. Its principal product candidate, Trexima is being developed in collaboration with GlaxoSmithKline for the treatment of acute migraine. Trexima is a proprietary single tablet containing sumatriptan succinate and naproxen sodium. The company entered into a collaboration agreement with AstraZeneca for the co-development and commercialization of proprietary fixed dose combinations of the proton pump inhibitor (PPI) esomeprazole...